Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands
- PMID: 34114187
- PMCID: PMC8191704
- DOI: 10.1007/s10654-021-00768-y
Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands
Abstract
Background: The proportion of SARS-CoV-2 positive persons who are asymptomatic-and whether this proportion is age-dependent-are still open research questions. Because an unknown proportion of reported symptoms among SARS-CoV-2 positives will be attributable to another infection or affliction, the observed, or 'crude' proportion without symptoms may underestimate the proportion of persons without symptoms that are caused by SARS-CoV-2 infection.
Methods: Based on two rounds of a large population-based serological study comprising test results on seropositivity and self-reported symptom history conducted in April/May and June/July 2020 in the Netherlands (n = 7517), we estimated the proportion of reported symptoms among those persons infected with SARS-CoV-2 that is attributable to this infection, where the set of relevant symptoms fulfills the ECDC case definition of COVID-19, using inferential methods for the attributable risk (AR). Generalised additive regression modelling was used to estimate the age-dependent relative risk (RR) of reported symptoms, and the AR and asymptomatic proportion (AP) were calculated from the fitted RR.
Results: Using age-aggregated data, the 'crude' AP was 37% but the model-estimated AP was 65% (95% CI 63-68%). The estimated AP varied with age, from 74% (95% CI 65-90%) for < 20 years, to 61% (95% CI 57-65%) for the 50-59 years age-group.
Conclusion: Whereas the 'crude' AP represents a lower bound for the proportion of persons infected with SARS-CoV-2 without COVID-19 symptoms, the AP as estimated via an attributable risk approach represents an upper bound. Age-specific AP estimates can inform the implementation of public health actions such as targetted virological testing and therefore enhance containment strategies.
Keywords: Asymptomatic disease; SARS-CoV-2; Serosurvey; The Netherlands.
© 2021. The Author(s).
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures

Similar articles
-
[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):200-206. doi: 10.19191/EP20.5-6.S2.119. Epidemiol Prev. 2020. PMID: 33412811 Italian.
-
Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.Microbiol Spectr. 2021 Sep 3;9(1):e0029121. doi: 10.1128/Spectrum.00291-21. Epub 2021 Aug 18. Microbiol Spectr. 2021. PMID: 34406813 Free PMC article.
-
Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.Clin Microbiol Infect. 2021 Mar;27(3):470.e1-470.e9. doi: 10.1016/j.cmi.2020.11.009. Epub 2020 Nov 20. Clin Microbiol Infect. 2021. PMID: 33221432 Free PMC article.
-
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.PLoS One. 2021 Jun 23;16(6):e0252617. doi: 10.1371/journal.pone.0252617. eCollection 2021. PLoS One. 2021. PMID: 34161316 Free PMC article.
-
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis.PLoS Med. 2022 May 26;19(5):e1003987. doi: 10.1371/journal.pmed.1003987. eCollection 2022 May. PLoS Med. 2022. PMID: 35617363 Free PMC article.
Cited by
-
Patterns of SARS-CoV-2 circulation revealed by a nationwide sewage surveillance programme, the Netherlands, August 2020 to February 2022.Euro Surveill. 2023 Jun;28(25):2200700. doi: 10.2807/1560-7917.ES.2023.28.25.2200700. Euro Surveill. 2023. PMID: 37347416 Free PMC article.
-
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?Vaccine. 2022 Apr 1;40(15):2251-2257. doi: 10.1016/j.vaccine.2022.03.009. Epub 2022 Mar 9. Vaccine. 2022. PMID: 35287986 Free PMC article.
-
Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.J Glob Health. 2022 Jul 25;12:03054. doi: 10.7189/jogh.12.03054. J Glob Health. 2022. PMID: 35871412 Free PMC article. No abstract available.
-
The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years.Eur J Epidemiol. 2022 Oct;37(10):1035-1047. doi: 10.1007/s10654-022-00895-0. Epub 2022 Aug 11. Eur J Epidemiol. 2022. PMID: 35951278 Free PMC article.
-
Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine.Open Forum Infect Dis. 2023 Apr 19;10(6):ofad209. doi: 10.1093/ofid/ofad209. eCollection 2023 Jun. Open Forum Infect Dis. 2023. PMID: 37274183 Free PMC article.
References
-
- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346. doi: 10.1371/journal.pmed.1003346. - DOI - PMC - PubMed
-
- Beale S, Hayward A, Shallcross L, Aldridge RW, Fragaszy E. Rapid review of the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections in community settings. medRxiv. 2020. 10.1101/2020.05.20.20108183.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous